Institutional Investors Betting on Novavax: How Lucrative is the Stock?

  • Institutional investors have increased their total NVAX holding from the first quarter to Q2.
  • The recent vaccine developments sustain NVAX, gaining 2.80%in five days.
  • The stock maintains massive bullishness, losing 86% YTD.

Massive stock holdings by institutional market players signal possible colossal price actions. That’s because wealthy investors might infuse the needed liquidity to support enormous market volatility.

Novavax’s NASDAQ: NVAX is among the stocks that have witnessed substantial institutional activity. The latest filings show key NVAX institutional holding has soared. The 2nd quarter had the firm filing 33.3 million stockholdings in NVAX.

Meanwhile, the stake surged from the first quarter’s 32.86 million shares. Among the firms that added NVAX shares during Q2 are Morgan Stanley and Vanguard. They bought 1.28 million and 7.35 million shares, respectively.

Coatue Management and State Street added 1.24 million and 2.96 million shares, respectively. Meanwhile, BlackRock represented sellers, renouncing 4.25 million shares. Also, funds holding NVAX plunged by 55 from the initial to the 2nd quarter.

The Latest Developments & Price Reactions

Novavax added 2.80% within the past five days because of attractive stock market news. The firm’s COVID vaccine encountered endpoints for Study 307 tests and PREVENT-19 trial. Also, there’s enthusiasm surrounding sharing Novavax’s vaccine collection throughout the World Vaccine Congress.

The 11 October to 14 October event might welcome opportunities for Novavax in the global vaccine space. NVAX has reacted to the optimistic sentiment. However, should you purchase the stock? NVAX isn’t impressive from a technical standpoint, as the stock maintains visible downtrends.

The shares come from the $16 oversold price. Nevertheless, the Relative Strength Index stays beneath the midpoint, confirming a substantial seller count. The current $20 price represents the least since May 2020, highlighting amplified selling momentum.

Should You Invest in NVAX?

NVAX remains mixed regardless of increased institutional investor holding. Crucial developments offer a trigger for a possible price surge. Nevertheless, the stock might retain massive bearishness before stable upticks.

What are your opinions about the biotech firm and its business projection? You can use the reply section below to leave a reply.